Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)
23.59
+0.35 (1.51%)
At close: Jul 3, 2026
SHA:603207 Revenue
Shanghai Xiao Fang Pharmaceutical had revenue of 145.69M CNY in the quarter ending March 31, 2026, with 12.88% growth. This brings the company's revenue in the last twelve months to 541.90M, up 13.19% year-over-year. In the year 2025, Shanghai Xiao Fang Pharmaceutical had annual revenue of 525.28M with 10.68% growth.
Revenue (ttm)
541.90M
Revenue Growth
+13.19%
P/S Ratio
7.00
Revenue / Employee
1.02M
Employees
529
Market Cap
3.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 525.28M | 50.70M | 10.68% |
| Dec 31, 2024 | 474.58M | 2.71M | 0.57% |
| Dec 31, 2023 | 471.87M | 14.98M | 3.28% |
| Dec 31, 2022 | 456.89M | 55.12M | 13.72% |
| Dec 31, 2021 | 401.77M | 40.54M | 11.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 25.24B |
| Jinling Pharmaceutical Company | 3.16B |
| Jinhe Biotechnology CO., LTD. | 2.99B |
| Nanjing Well Pharmaceutical Group | 1.34B |
| Zhuhai Rundu Pharmaceutical | 1.27B |
| Tibet Weixinkang Medicine | 1.16B |
| LanZhou Foci Pharmaceutical | 910.98M |
| Shandong Wohua Pharmaceutical | 818.16M |